arrow
G

Giancarlo Orofino

University of Catania
H指数:29
被引数:2,875

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Obesity at antiretroviral therapy initiation and long-term risk of cardiovascular disease, cancer, or death in people with HIV in Italy: a prospective cohort study

在意大利,HIV感染者抗逆转录病毒治疗启动时的肥胖与心血管疾病、癌症或死亡的长期风险:一项前瞻性队列研究

2026-08-010
PRE
Distance from low-density lipoprotein cholesterol targets across cardiovascular risk strata in people living with HIV: A multicentre cohort study

HIV感染者中低密度脂蛋白胆固醇目标值的达标距离及其心血管风险分层:一项多中心队列研究

2026-07-010
OA
Bimonthly Administered Long-Acting Cabotegravir and Rilpivirine Are Highly Effective and Well-Tolerated in People With Human Immunodeficiency Virus Above 65 Years

每两个月给药的长效卡博特韦和 rilpivirine 在 65 岁以上的人类免疫缺陷病毒感染者中具有高效性和良好的耐受性

2026-01-010
PRE
All-Cause Mortality in People With Four-Class Drug-Resistant Human Immunodeficiency Virus: A Matched Cohort Analysis With Data From the PRESTIGIO Registry

四类耐药人类免疫缺陷病毒患者全因死亡率:一项基于PRESTIGIO登记数据的匹配队列分析

2025-08-010
OAAI
Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA Study
2024-04-153
OAAI
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort
2024-04-063
PRE
Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting

具有抗逆转录病毒治疗经验的HIV感染者的脂质和转氨酶,转换为基于Doravirine的方案与基于Rilpivirine的方案: 来自现实生活中的数据

2023-07-238
OAAI
Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens
2023-04-145
OAAI
Incident diabetes in course of antiretroviral therapy

在抗逆转录病毒治疗过程中发生糖尿病

AIDS
IF3.1
2023-03-145
PRE
Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study
2023-03-108
OAAI
Trajectories of CD4+/CD8+ T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study
2022-10-222
OAAI
Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?
2022-09-239
OAAI
Reversibility of Central Nervous System Adverse Events in Course of Art
2022-05-1110
OAAI
Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study
2021-09-0118
PRE